繁體版 / 簡體版
 
R&D PORTFOLIO
/ MB-6

MB-6

Indication
Acting as Adjuvant for metastatic colorectal cancer
Product Advantages
reducing chemo-associated toxicity and enhancing efficacy of chemotherapy
Status
Phase III clinical trial is in progress
Competitive Edge
Oral capsule botanical drug, high safety, not much similar drugs currently on the market or under development
Potential Market
The analysis by GBI Research points out that the market value of colorectal cancer treatment will increase from 8.3 billion U.S. dollars in 2013 to 9.4 billion U.S. dollars in 2020
  • A series of preclinical studies had demonstrated that MB-6 reduced the incidence of colonic polyps and formation of tumor, prolonged survival rate as compared to chemotherapy alone when MB-6 was given together with 5-FU in colorectal cancer bearing mice.
  • MB-6 obtained USFDA and Taiwan Ministry of Health and Welfare (MOHW) phase II IND approval. In the Phase II clinical trials of patients with colorectal cancer in Taiwan, the combination of MB-6 and FOLFOX-4 standard treatment significantly prolonged progression-free survival (PFS) and overall survival, improved chemotherapeutic compliance, and improved FOLFOX-4-induced Neutropenia and reduce the dose of granulocyte colony stimulating factor (G-CSF) used

Phase II clinical trial


好玩棋牌 今天体育彩票中奖号码 内蒙古快3走势跨度 山东体彩11选5中奖规则 查找吉林十一选五走势图 吉林11选5遗漏数据 71豆幸运28预测 广东十一选五一定牛走 云天化股票行情 重庆时时计划手机软件下载 北京快三开奖结果最新